Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG

Sangeetha Iyer, Ethan Perlstein
Disease Models & Mechanisms
January 1, 2019
10.1242/dmm.040584
Cited by 78

Related Papers

Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic Implications
|Annals of Neurology|2021|57
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
|bioRxiv (Cold Spring Harbor Laboratory)|2019|32